YU7499A - Kristalni oblik 4-[5-metil-3-fenilizoksazol-4-il]benzolsulfonamida - Google Patents
Kristalni oblik 4-[5-metil-3-fenilizoksazol-4-il]benzolsulfonamidaInfo
- Publication number
- YU7499A YU7499A YU7499A YU7499A YU7499A YU 7499 A YU7499 A YU 7499A YU 7499 A YU7499 A YU 7499A YU 7499 A YU7499 A YU 7499A YU 7499 A YU7499 A YU 7499A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- methyl
- crystalline form
- phenylisoxasol
- benzenesulphonamide
- stable
- Prior art date
Links
Classifications
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L23/00—Details of semiconductor or other solid state devices
- H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
- H01L23/40—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs
- H01L23/4006—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs with bolts or screws
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L23/00—Details of semiconductor or other solid state devices
- H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
- H01L23/42—Fillings or auxiliary members in containers or encapsulations selected or arranged to facilitate heating or cooling
- H01L23/427—Cooling by change of state, e.g. use of heat pipes
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
- H01L2924/0001—Technical content checked by a classifier
- H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Power Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Computer Hardware Design (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Liquid Crystal Substances (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
Abstract
Opisan je stabilan kristalni oblik 4-[5-metil-3-fenilizoksazol-4-il]benzolsulfonamida. Ova kristalna struktura označena kao Oblik B, je stabilnija, ima pogodne osobine za manipulisanje i karakteriše se njegovom tačkom topljenja, X-zracima i drugim fizičkim karakterizacijama.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2437896P | 1996-08-14 | 1996-08-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU7499A true YU7499A (sh) | 2000-03-21 |
| RS49671B RS49671B (sr) | 2007-11-15 |
Family
ID=21820280
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US6441014B2 (sh) |
| EP (2) | EP0920422B1 (sh) |
| JP (2) | JP3631763B2 (sh) |
| KR (1) | KR100383148B1 (sh) |
| CN (1) | CN1205193C (sh) |
| AP (1) | AP1055A (sh) |
| AR (1) | AR009244A1 (sh) |
| AT (1) | ATE228117T1 (sh) |
| AU (1) | AU722072B2 (sh) |
| BG (1) | BG64259B1 (sh) |
| BR (1) | BR9711151A (sh) |
| CA (1) | CA2264104A1 (sh) |
| CZ (1) | CZ297679B6 (sh) |
| DE (1) | DE69717281T2 (sh) |
| DK (1) | DK0920422T3 (sh) |
| EA (2) | EA003754B1 (sh) |
| EE (1) | EE04237B1 (sh) |
| ES (1) | ES2188971T3 (sh) |
| GE (1) | GEP20022636B (sh) |
| HK (1) | HK1023125A1 (sh) |
| HU (1) | HUP0400923A3 (sh) |
| IL (2) | IL161224A0 (sh) |
| IS (1) | IS1989B (sh) |
| LT (1) | LT4551B (sh) |
| LV (1) | LV12274B (sh) |
| NO (1) | NO312461B1 (sh) |
| NZ (1) | NZ334132A (sh) |
| OA (1) | OA11298A (sh) |
| PL (1) | PL191313B1 (sh) |
| PT (1) | PT920422E (sh) |
| RO (1) | RO120771B1 (sh) |
| RS (1) | RS49671B (sh) |
| SI (1) | SI9720059B (sh) |
| SK (1) | SK283558B6 (sh) |
| TR (1) | TR199900298T2 (sh) |
| TW (1) | TW527350B (sh) |
| UA (1) | UA52684C2 (sh) |
| WO (1) | WO1998006708A1 (sh) |
| ZA (1) | ZA977314B (sh) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199900298T2 (xx) * | 1996-08-14 | 1999-05-21 | G.D. Searle &Co. | 4-(5-Metil-3-fenilizoksazol-4-il) BenzenS�lfonamidin kristal halinde bi�imi. |
| NZ333399A (en) | 1997-12-24 | 2000-05-26 | Sankyo Co | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis |
| GB9810920D0 (en) * | 1998-05-21 | 1998-07-22 | Merck Sharp & Dohme | Therapeutic use |
| EP1102755B1 (en) * | 1998-08-07 | 2006-01-04 | Chiron Corporation | Substituted isoxazole derivatives as estrogen receptor modulators |
| AU1398899A (en) * | 1998-11-12 | 2000-06-05 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with centrally acting analgesics |
| CN1349423A (zh) * | 1999-03-01 | 2002-05-15 | 奥索-麦克尼尔药品公司 | 包含曲马多物质和选择性cox－2抑制剂药物的组合物 |
| ATE284223T1 (de) * | 1999-08-20 | 2004-12-15 | Ortho Mcneil Pharm Inc | Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel |
| US6403640B1 (en) * | 1999-08-27 | 2002-06-11 | Merck & Co., Inc. | Method for treating chronic prostatitis or chronic pelvic pain syndrome |
| DE10032132A1 (de) * | 2000-07-01 | 2002-01-17 | Lohmann Therapie Syst Lts | Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung |
| DK1419151T3 (da) | 2001-08-15 | 2014-03-31 | Pharmacia & Upjohn Co Llc | Krystaller indeholdende et malatsyresalt af N-[2-(diethylamino)ethyl]-5-[(5-fluor-1,2-dihydro-2-oxo-3H-indol-3-yliden)methyl]-2,4-dimethyl-1H-pyrrol-3-carboxyamid, fremgangsmåder til fremstilling deraf og sammensætninger deraf |
| US20070072921A1 (en) * | 2002-07-26 | 2007-03-29 | Talley John J | Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide |
| AU2003238668A1 (en) | 2003-04-04 | 2004-10-25 | Hetero Drugs Limited | Novel crystalline forms of valdecoxib |
| PL1534305T3 (pl) | 2003-05-07 | 2007-03-30 | Osteologix As | Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie |
| US20050182113A1 (en) * | 2003-12-30 | 2005-08-18 | Venkataraman Sundaram | Method for preparing diaryl-substituted isoxazole compounds |
| US20050272787A1 (en) * | 2004-05-19 | 2005-12-08 | Eswaraiah Sajja | Process for preparing crystalline form A of valdecoxib |
| WO2005120499A1 (en) * | 2004-06-10 | 2005-12-22 | Chandiran Thakashinamoorthy | Form a of valdecoxib suitable for pharmaceutical formulations |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| ES2291780T3 (es) * | 2004-06-28 | 2008-03-01 | Grunenthal Gmbh | Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol. |
| KR100591786B1 (ko) | 2004-10-19 | 2006-06-26 | 휴먼팜 주식회사 | 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법 |
| EP1881959A1 (en) | 2005-05-20 | 2008-01-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US8492431B2 (en) | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| JP2009537635A (ja) | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
| US8809385B2 (en) | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| CN103172583A (zh) * | 2013-03-07 | 2013-06-26 | 深圳市资福药业有限公司 | 一种制备帕瑞昔布的方法 |
| US10028904B2 (en) | 2014-12-04 | 2018-07-24 | Wisconsin Alumni Research Foundation | Transdermal cannabinoid formulations |
| US9375417B2 (en) | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
| CN114441666B (zh) * | 2020-11-05 | 2024-02-27 | 成都百裕制药股份有限公司 | 一种4-(5-甲基-3-苯基-4-异恶唑)苯磺酰氯中杂质的检测方法 |
| IL305573A (en) | 2021-03-15 | 2023-10-01 | Saul Yedgar | Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| WO1996025405A1 (en) * | 1995-02-13 | 1996-08-22 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| US5643933A (en) * | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| TR199900298T2 (xx) * | 1996-08-14 | 1999-05-21 | G.D. Searle &Co. | 4-(5-Metil-3-fenilizoksazol-4-il) BenzenS�lfonamidin kristal halinde bi�imi. |
| AU2003238668A1 (en) * | 2003-04-04 | 2004-10-25 | Hetero Drugs Limited | Novel crystalline forms of valdecoxib |
| US20050272787A1 (en) * | 2004-05-19 | 2005-12-08 | Eswaraiah Sajja | Process for preparing crystalline form A of valdecoxib |
-
1997
- 1997-08-12 TR TR1999/00298T patent/TR199900298T2/xx unknown
- 1997-08-12 PL PL331607A patent/PL191313B1/pl not_active IP Right Cessation
- 1997-08-12 EA EA200000891A patent/EA003754B1/ru not_active IP Right Cessation
- 1997-08-12 DE DE69717281T patent/DE69717281T2/de not_active Expired - Fee Related
- 1997-08-12 HU HU0400923A patent/HUP0400923A3/hu unknown
- 1997-08-12 SK SK136-99A patent/SK283558B6/sk not_active IP Right Cessation
- 1997-08-12 SI SI9720059A patent/SI9720059B/sl not_active IP Right Cessation
- 1997-08-12 CZ CZ0033499A patent/CZ297679B6/cs not_active IP Right Cessation
- 1997-08-12 NZ NZ334132A patent/NZ334132A/en unknown
- 1997-08-12 CA CA002264104A patent/CA2264104A1/en not_active Abandoned
- 1997-08-12 ES ES97938656T patent/ES2188971T3/es not_active Expired - Lifetime
- 1997-08-12 RO RO99-00176A patent/RO120771B1/ro unknown
- 1997-08-12 AP APAP/P/1999/001458A patent/AP1055A/en active
- 1997-08-12 BR BR9711151A patent/BR9711151A/pt not_active Application Discontinuation
- 1997-08-12 WO PCT/US1997/015126 patent/WO1998006708A1/en active IP Right Grant
- 1997-08-12 PT PT97938656T patent/PT920422E/pt unknown
- 1997-08-12 IL IL16122497A patent/IL161224A0/xx unknown
- 1997-08-12 AU AU40936/97A patent/AU722072B2/en not_active Ceased
- 1997-08-12 JP JP51012198A patent/JP3631763B2/ja not_active Expired - Fee Related
- 1997-08-12 KR KR10-1999-7001263A patent/KR100383148B1/ko not_active IP Right Cessation
- 1997-08-12 EA EA199900200A patent/EA001472B1/ru not_active IP Right Cessation
- 1997-08-12 IL IL12825597A patent/IL128255A/en not_active IP Right Cessation
- 1997-08-12 EP EP97938656A patent/EP0920422B1/en not_active Expired - Lifetime
- 1997-08-12 EP EP02025507A patent/EP1283203A1/en not_active Withdrawn
- 1997-08-12 CN CNB971985367A patent/CN1205193C/zh not_active Expired - Fee Related
- 1997-08-12 EE EEP199900053A patent/EE04237B1/xx not_active IP Right Cessation
- 1997-08-12 DK DK97938656T patent/DK0920422T3/da active
- 1997-08-12 AT AT97938656T patent/ATE228117T1/de not_active IP Right Cessation
- 1997-08-12 GE GEAP19974712A patent/GEP20022636B/en unknown
- 1997-08-14 ZA ZA977314A patent/ZA977314B/xx unknown
- 1997-08-14 AR ARP970103706A patent/AR009244A1/es not_active Application Discontinuation
- 1997-10-14 TW TW086111783A patent/TW527350B/zh not_active IP Right Cessation
- 1997-12-08 UA UA99031377A patent/UA52684C2/uk unknown
-
1999
- 1999-01-29 IS IS4961A patent/IS1989B/is unknown
- 1999-02-05 NO NO19990541A patent/NO312461B1/no unknown
- 1999-02-08 BG BG103155A patent/BG64259B1/bg unknown
- 1999-02-12 OA OA9900031A patent/OA11298A/en unknown
- 1999-02-12 RS YUP-74/99A patent/RS49671B/sr unknown
- 1999-03-05 LV LVP-99-40A patent/LV12274B/en unknown
- 1999-03-10 LT LT99-024A patent/LT4551B/lt active Protection Beyond IP Right Term
-
2000
- 2000-04-19 HK HK00102376A patent/HK1023125A1/xx not_active IP Right Cessation
- 2000-12-19 US US09/741,213 patent/US6441014B2/en not_active Expired - Fee Related
-
2002
- 2002-07-26 US US10/205,732 patent/US7135489B2/en not_active Expired - Fee Related
-
2004
- 2004-10-15 JP JP2004301644A patent/JP2005015497A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU7499A (sh) | Kristalni oblik 4-[5-metil-3-fenilizoksazol-4-il]benzolsulfonamida | |
| BR9911001A (pt) | Processo de aquisição de comunicações para um terminal de usuário com um sistema de comunicações de radiotelefone, terminal de usuário, e, processo de varredura de canais de comunicações para um terminal de usuário de uso duplo. | |
| UY24819A1 (es) | Nuevos compuestos | |
| DK1191926T3 (da) | Ny omeprazol- og (S)-omeprazolformulering | |
| NO20032645L (no) | Heterocykliske sulfonamidinhibitorer av <beta>- amyloidproduksjonen | |
| BR9903786A (pt) | Método para determinar identificadores temporários de aparelhos móveis e administrar o seu uso | |
| BR0206834A (pt) | Circuito de polarização papa manter um valor constante de transcondutância dividida pela capacitância de carga | |
| MX9305027A (es) | 4- 2-(4-(2-piridiniloxi)fenil)etoxi] quinazolina yanalogos de la misma. | |
| EA200300067A1 (ru) | Кристаллическая форма целекоксиба | |
| DK1305037T3 (da) | Smertestillende medikament | |
| BR0110258A (pt) | Cristal estável de derivado de tiazolidinadiona e processo para sua produção | |
| SE7705310L (sv) | Kinazolinderivat | |
| BR9915836A (pt) | Método de uso em um primeiro nó de uma rede de comunicação, uso do mesmo, nó de uma rede de comunicação, e, rede de comunicação | |
| BR8506369A (pt) | Conjunto de um dispositivo contraceptivo intra-uterino e correspondente insertor,insertor para uso no conjunto e respectivo dispositivo | |
| BR0215819A (pt) | Arquitetura de armazenamento temporário centralizado para um receptor de multiplexação por divisão de frequência ortogonal (ofdm) | |
| EE03666B1 (et) | AII-retseptori antagonistide uus farmakoloogilinekasutus | |
| SE9504662D0 (sv) | New compounds | |
| YU82693A (sh) | Farmaceutske formulacije disulfonil metana i novi disulfonil metani | |
| DK69190A (da) | Mutanter af urinaer plasminogenaktivator, deres fremstilling af anvendelse | |
| DE69418478T2 (de) | Herbizide pyridinverbindungen | |
| DK0589903T3 (da) | Aminoalkylsubstituerede 5-mercaptothiazoler, deres fremstilling og anvendelse | |
| DK0619734T3 (da) | Nye farmaceutiske formuleringer af 5-(2-chlor-1-hydroxyethyl)-4-methylthiazol | |
| SE9904553D0 (sv) | A telecommunication device | |
| JPS63236436A (ja) | ネ−ムサ−ビスシステム | |
| DK0592453T3 (da) | Aminoalkylsubstituerede 2-amino-1,3,4-thiadiazoler, deres fremstilling og deres anvendelse |